Skip to main content
    O

    Opus Genetics, Inc. (IRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.18
    +0.17 (+4.37%)

    Market Cap: $333.20M

    Last updated: Nov 06, 2026 at 4:26 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(19/38)
    Avg Surprise
    -616.80%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.21 - $-0.09
    12 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.16+3.2%
    60d ago$-0.15-0.3%
    30d ago$-0.150.0%
    7d ago$-0.150.0%
    Current$-0.15
    Revenue Consensus
    $2M
    Range$0 - $7M
    18 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.49
    Range$-0.79 - $0.17
    12 analysts
    Revenue Consensus
    $6M
    Range$-4683060 - $21M
    18 analysts
    Last 12 of 39 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.49$-0.79 - $0.17--12--
    Sep 26EST
    		-$-0.15$-0.21 - $-0.09--12
    1
    0
    30d
    		-
    Jun 26
    Reported Aug 6
    		$-0.14$-0.15$-0.27 - $-0.09+6.67%Beat13
    0
    1
    30d
    		-16.7%
    Mar 26
    Reported May 12
    		$-0.75$-0.14$-0.18 - $-0.09-435.71%Miss6
    0
    1
    30d
    		-134.4%
    Dec 25
    Reported Feb 25
    		$-0.21$-0.12$-0.13 - $-0.11-78.27%Miss3
    No revisions (30d)
    		+83.5%
    Sep 25
    Reported Nov 12
    		$-0.25$-0.13$-0.13 - $-0.13-92.31%Miss1
    No revisions (30d)
    		+13.8%
    Jun 25
    Reported Aug 13
    		$-0.12N/A-+53.85%Beat--+60.0%
    Mar 25
    Reported May 15
    		$-0.32$-0.34$-0.34 - $-0.34+5.88%Beat1
    No revisions (30d)
    		-10.3%
    Dec 24
    Reported Mar 31
    		$-1.27$-0.05$-0.34 - $0.55-2573.68%Miss3
    0
    2
    30d
    		-504.8%
    Sep 24
    Reported Nov 12
    		$-0.29$-0.23--26.09%Miss---216.0%
    Jun 24
    Reported Aug 13
    		$-0.30$-0.28--7.14%Miss---25.0%
    Mar 24
    Reported May 10
    		$-0.29$-0.14--107.14%Miss---3.6%
    Dec 23
    Reported Mar 8
    		$-0.21$-0.05--320.00%Miss---112.4%
    Sep 23
    Reported Nov 13
    		$0.25$-0.23-+208.70%Beat--+213.6%

    Key Metrics

    Valuation
    P/E Ratio-3.10EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-2183.00%
    ROE-4797.00%ROIC-365.47%
    Financial Health
    Debt/Equity-2.79xInterest CoverageN/A
    Current Ratio12.19xQuick Ratio12.19x
    Trading Statistics
    Beta0.81Avg Volume1.34M
    52-Week High$7.0752-Week Low$1.70

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.79
    SMA 20$3.90
    SMA 50$4.47
    SMA 200$4.23
    EMA 10$3.94
    EMA 20$4.00
    EMA 50$4.18
    EMA 200$3.88

    MACD

    Line: -0.12Signal: -0.20Hist: 0.08

    ADX

    ADX: 14.5+DI: 26.5-DI: 25.7

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down64.0
    PSAR$3.33

    Bollinger Bands

    Upper Band$4.54
    Lower Band$3.26
    %B Position3284%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    52.6

    Momentum Oscillators

    Stoch %K84.6
    Stoch %D76.6
    Williams %R-12.8
    ROC (10d)20.5%
    Momentum0.71
    CCI (20d)58.2
    MFI (14d)63.1

    Volatility Measures

    ATR (14d)$0.32(7.8%)
    StdDev (20d)0.32
    Hist Vol83.6%(High)

    Volume Flow

    VWAP$4.14
    OBV127.3M
    AD Line-61.2M
    CMF (20d)-0.158

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.6x
    VWMA (20d)$3.92

    Pivot Points

    R3$4.72
    R2$4.49
    R1$4.25
    Pivot Point$4.02
    S1$3.78
    S2$3.55
    S3$3.31

    Advanced Oscillators

    TSI-11.16
    Ultimate Osc59.2
    KST-189.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$755,000$2.16M$3.87M$3.08M$2.88M$4.37M$4.30M$3.87M$1.11M$1.71M$1.69M$11.94M
    Cost of Revenue$0$0$13,000$0$0$0$7.78M$0$0$0$4.70M$0
    Gross Profit$755,000$2.16M$3.87M$3.08M$2.88M$4.37M$4.30M$3.87M$1.11M$1.71M$1.69M$11.94M
    Operating Expenses$17.23M$16.52M$15.32M$11.39M$11.79M$14.30M$42.33M$11.88M$9.44M$9.42M$7.12M$5.55M
    R&D$11.21M$10.58M$10.43M$6.41M$6.02M$7.95M$35.03M$8.98M$6.09M$4.75M$3.84M$3.49M
    SG&A$6.03M$5.94M$4.89M$4.98M$5.77M$6.35M$7.30M$2.89M$3.35M$4.67M$3.28M$2.06M
    Operating Income$-16,480,000$-14,364,000$-11,453,000$-8,311,000$-8,906,000$-9,929,000$-38,029,000$-8,009,000$-8,328,000$-7,708,000$-5,429,000$6.39M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$69,000$5.07M$68,000$0$0$0$0$0$0$0$811,000
    Income Before Tax$-8,098,000$-65,535,000$-16,523,000$-17,454,000$-7,420,000$-8,194,000$-35,135,000$-7,526,000$-7,765,000$-7,106,000$-4,797,000$5.58M
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$-2,000$14,000
    Net Income$-8,098,000$-65,535,000$-16,523,000$-17,454,000$-7,420,000$-8,194,000$-35,135,000$-7,526,000$-7,765,000$-7,106,000$-4,795,000$5.56M
    EBITDA$-8,084,000$-65,453,000$-16,449,000$-17,373,000$-7,406,000$-8,181,000$-35,125,000$-7,526,000$-7,765,000$-7,106,000$-4,794,000$5.58M
    EBIT$-8,098,000$-65,466,000$-16,462,000$-17,386,000$-7,420,000$-8,194,000$-35,135,000$-7,526,000$-7,765,000$-7,106,000$-4,797,000$5.58M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IRD

    IRD Valuation and Fair Value

    P/E
    -3.1x
    Forward P/E
    12.0x
    P/B
    -30.7x
    See GNG's fair value

    IRD Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -2183.0%
    Net margin
    0.0%
    ROIC
    -365.5%
    ROE
    -4797.0%

    IRD Competitors

    CompanyTicker
    Semler Scientific IncSMLR
    Community Health Systems IncCYH
    Orchestra BioMed Holdings Inc.OBIO
    Prenetics Global LtdPRE
    Viemed Healthcare IncVMD
    X4 Pharmaceuticals IncXFOR
    Contineum Therapeutics, Inc. Class A Common StockCTNM
    Canopy Growth CorpCGC

    Sector: Healthcare

    IRD Analyst Ratings

    Consensus
    Buy
    Analysts
    18
    Strong Buy
    3
    Buy
    15
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IRD Bull Case vs Bear Case

    Bull case

    • 100.0% of IRD's analyst ratings are Buy or Strong Buy.

    Bear case

    • IRD beat EPS estimates in 37.5% of its last 8 reported quarters.
    • IRD's quarterly revenue changed -73.8% year over year.

    IRD Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -392.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    IRD Earnings Date

    IRD reports Nov 10, 2026. The date is estimated.

    IRD ETF Holders

    GNG tracks 3 ETFs that hold IRD. The largest weights:

    1. Fidelity Enhanced Small Cap Core ETF (FESM), 0.01% of the fund
    2. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    3. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for IRD

    Frequently Asked Questions About IRD

    When does IRD report earnings?

    Opus Genetics, Inc. (IRD) is expected to report earnings on Nov 10, 2026.

    Does IRD pay dividends?

    Opus Genetics, Inc. (IRD) does not currently pay a regular dividend.

    What is IRD's market cap?

    Opus Genetics, Inc. (IRD) has a market capitalization of $333.20M with a current stock price of $4.18.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In